Ramona Dadu


Affiliation: The University of Texas
Country: USA


  1. Iyer P, Cabanillas M, Waguespack S, Hu M, Thosani S, Lavis V, et al. Immune Checkpoint Inhibitor mediated Thyroiditis. Thyroid. 2018;: pubmed publisher
    ..The evolution of irT is more rapid with combination ICI. Frequent monitoring of TFTs during ICI is warranted. Future guidelines need to recognize this entity and incorporate their management. ..
  2. Tam S, Boonsripitayanon M, Amit M, Fellman B, Li Y, Busaidy N, et al. Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging 7th and 8th editions. Thyroid. 2018;: pubmed publisher
    ..Potential modifications that may improve disease-specific survival prediction in future renditions include reconsideration of T3b tumor category and upstaging classification of patients < 55 years of age with distant metastases. ..
  3. Cabanillas M, Ferrarotto R, Garden A, Ahmed S, Busaidy N, Dadu R, et al. Neoadjuvant BRAF- and immune- directed therapy for anaplastic thyroid carcinoma. Thyroid. 2018;: pubmed publisher
    ..This novel neoadjuvant approach to BRAF-mutated ATC should be studied in further in clinical trials. ..
  4. Iyer P, Dadu R, Ferrarotto R, Busaidy N, Habra M, Zafereo M, et al. Real world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid. 2017;: pubmed publisher
    ..Patients with anaplastic thyroid cancer (ATC) have a dismal prognosis despite systemic cytotoxic chemotherapy. Our objective was to study the efficacy and safety of targeted therapy in ATC patients when used outside of a clinical trial...